Algen
AI-powered causal biology for drug discovery
San Francisco, CA, US
Algen is a platform company focused on drug target discovery, utilizing CRISPR technology and machine learning to decode causal biology and identify disease-driving mechanisms. It also focuses on RNA message modulation at single-cell resolution.
Problem Statement
The difficulty in decoding causal biology and identifying disease-driving mechanisms for effective drug target discovery.
Core Technology
CRISPR technology, machine learning, RNA message modulation at single-cell resolution, AlgenBrain platform for AI-powered drug discovery
Key Differentiators
Utilizes CRISPR technology and machine learning to decode causal biology; Focuses on RNA message modulation at single-cell resolution; Spun out from UC Berkeley Nobel laureate Jennifer Doudna's lab; AlgenBrain platform for AI-powered drug discovery
Clinical Focus
Immuno-oncology; Autoimmune diseases
Company Info
- Business Model
- Other
- Founded
- 2018
- Total Funding
- 12,630,000
- Website
- www.algen.co
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Lead oncology candidate preparing for clinical trials; $555M AstraZeneca partnership validates scientific approach
MedStartr Index Score
?What do you think of Algen?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.